		(ii) Sulphamethaxazole
		(iii) Clopamide
		(iv) Lectobionate
3	M/s. E. Merck India Ltd.	(i) Vitamin E

Action on this was to be taken by the Departments concerned with the administration of Duty Drawback and Cash Compensatory Support.

(d) and (e) Prices of bulk drugs and formulations are fixed/revised in accordance with the provision of DPCO 1987. For this purpose necessary expert recommendations are obtained from RICP who scrutinise and process cases of formulation prices and take up cost-cum-technical study, including on-the-spot verification in respect of bulk drugs.

Price rise in imported formulations

736. SHRI SANTOSH KUMAR SAHU: Will the PRIME MINISTER be pleased to state:

(a) whether it is a fact that prices of imported formulations have gone up considerably despite the fact that most of these medicines have been exempted from customs duty;

(b) what are the names of imported formulations whose prices have been increased after the announcement of DPCO, 1987 and what was its earlier and present price;

(c) what are the names of products where either customs duty has been exempted or reduced after the announcement of DPCO, 1987 and what was the price before exemption and after exemption; and

(d) when was the price of each reduced?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) to (d) Under the conditions of alround increase in the costs, the prices are bound to go up, more so, in cases of imported items, including medcines, due to adjustment in the exchange rate of Indian rupees against major foreign currencies, availability of foreign exchange at market rate etc. Steps like exemption from custom duty etc. are aimed at mitigating the situation to the extent possible. Prices of imported formulations are on batch bases and can vary even from batch to batch depending on international market situation at the time of import. The number of products and their batches are so large that time and labour involved in collecting the requisite details would not be commensurate with the results likely to be achevved.

Bulk drugs and formulations under Industrial Licensing Regime

737. SHRI P. UPENDRA: Will the PRIME MINISTER be pleased to state:

(a) whether all bulk drugs and formulation have fallen under the industrial licensed regime due to "technical error" by Government; and

(b) if so, the reason for deviating from the delicensing-oriented policy of Government?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) and (b) Bulk drugs and formulations have been placed